China NMPA New Regulation 2026: What Brands Must Know | QuickOEM

China's National Medical Products Administration (NMPA) is expected to roll out a set of cosmetics regulatory updates through 2026 that reshape how brands file products, prove efficacy, and stay inspection-ready. Reported and expected changes touch children's cosmetics, sun protection, efficacy substantiation, imported-product filing, and penalties. This guide breaks down what is shifting and how beauty brands, OEM/ODM partners, and foreign importers should prepare.

1. Children's Cosmetics: Tighter Safety Assessment

Reported to take effect from 1 June 2026, the upgraded rules for children's cosmetics (products intended for under-12s) raise the bar on the safety evidence that brands and their manufacturers must hold.

• Skin compatibility testing: irritation and sensitivity assessments are required, with extra specialist evaluation for products aimed at children under 3.
• Preservative limits: the typical concentration ceiling for certain preservatives in child-specific products is reported to fall from about 1% to roughly 0.4%, with phenoxyethanol and similar actives facing closer review.
• Fragrance allergen labelling: the 26 EU-recognised fragrance allergens must be declared in a prominent label position.
• Responsible assessment: the safety assessment report must be signed by a registered safety assessor, and qualification requirements are higher.

For OEM brands this means child-facing product lines need formula re-evaluation; adjusting preservative systems early is the pragmatic move before the deadline.

2. Sun Protection: New SPF and UVA Testing Standards

The expected SPF testing update moves sun care toward in vivo evidence rather than laboratory-only data.

• SPF 50+ products: validation through in vivo (human) testing, with pure in vitro data no longer accepted on its own.
• High UVA protection (PA++ and above): in vivo UVA-PF test reports are required.
• Spray formats: an additional inhalation safety assessment is expected for mist sunscreens.

Timelines reported: new-item registration applies from 1 October 2026, with existing mass-production stock transitioned by 1 April 2027. Brands should pre-book testing capacity now to avoid a bottleneck.

3. Efficacy Claims Need Substantiation

Generic claims such as "brightening" and "anti-aging" are no longer accepted without support. Under the expected rules, each claim must sit on a defined evidence tier: consumer testing, instrumental measurement, or a clinical study. Brands should map every claim on every SKU to a documented file.

Honest boundary: no single active is a magic bullet. The right one earns its place through tolerance, stability, and fit with your brand story.

This shift rewards disciplined brands and pressures those that have leaned on vague marketing language. Start the claim audit before the dossier is due, because a single unsupported claim can now stall an entire filing rather than just a single product page.

4. Full-Ingredient Disclosure: Cleaner Dossiers

Alongside claims, the 2026 direction points to stricter, more complete ingredient disclosure. Brands should expect NMPA to ask for the full INCI list with concentration ranges, functions, and the safety data behind each item, not just a packaging-facing summary.

• Concentration transparency: reported expectation is that actives and preservatives show typical use levels, so regulators can judge exposure at a glance.
• Restricted-substance watch: keep a live cross-check against NMPA positive and negative lists, since banned or capped materials differ from EU and US tables.
• Supplier evidence: raw-material certificates of analysis and specs should be filed per batch, ready for spot checks.

For contract manufacturers this is a sourcing discipline as much as a paperwork one: a factory that cannot trace an ingredient to its certificate will become a compliance liability, not just a production partner.

5. Imported Cosmetics: Faster Filing and Review Pilot

There is a brighter side for foreign brands. NMPA is reported to have launched a technical review speed pilot in key zones: Shanghai, Guangzhou, and Beijing.

• Ordinary import filing: expected turnaround cut from about 5 to 3 working days in pilot areas.
• High-risk special cosmetics: approval target shortened from roughly 18 to 12 months under full compliance.
• Issue flagging: a problem-detection system aims to return technical feedback within about 10 days of acceptance.

For foreign brands entering China, this compresses time-to-shelf, provided the dossier is clean on first submission.

6. Labelling Violations: Penalties Escalate

From 2026, labelling breaches are reported to move from corrective orders to direct fines and public action.

• Unsubstantiated efficacy claims: fines up to an approximate threshold, plus products pulled from shelves.
• Ingredient list errors or omissions: batch recall plus a fine.
• Children's cosmetics labelling irregularities: sales suspension and full distribution-channel verification.

Penalty amounts vary by case and should be confirmed against the latest NMPA guidance; treat the figures above as typical, not definitive.

What This Means for OEM/ODM and Foreign Brands

The 2026 updates push compliance upstream, into formulation, testing, and dossier quality, rather than after-the-fact fixes. OEM/ODM manufacturers become a front-line control point: their formula records, preservative choices, and claim support now directly determine a brand's market access in China.

Foreign brands should expect heavier documentation at import and tighter claim rules in-market. Building a China-ready dossier early, with a qualified local responsible person where required, avoids the costly rework that follows a rejected filing.

How to Prepare: A Practical Checklist

First half of 2026

• Audit child product lines and assess whether preservative systems need adjustment before June.
• Verify existing SPF test methods and pre-arrange retesting where they fall short of the in vivo standard.
• Inventory every efficacy claim across your catalogue and the data that supports it.

Second half of 2026

• Digitise efficacy-claim evidence into a retrievable file per SKU.
• Refresh label artwork, reserving clear space for fragrance-allergen declarations.
• Engage a qualified local responsible person and pre-submit pilot-zone filings where eligible.

Platforms such as QuickOEM help brands shortlist factories and compliance partners with NMPA filing experience, so formulation and dossier work stay aligned from day one.